GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Tovorafenib - OJEMDA tablets / oral suspension

Read renal action and limits
Local official-label summarySource retrieved 2026-11-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

OJEMDA / tovorafenib

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

OJEMDA: source applicability and renal evidence limits

The primary label has an explicit renal-use recommendation; the retrieved mirror passage is PK-only. Absence of that section in the returned mirror text is not proof of disagreement.

Before applying: Use age-appropriate Schwartz/MDRD interpretation and the labeled oncology regimen.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

OJEMDA: selected primary-label renal guidance and limits

This source only - not a merged recommendation

What matters first

Product: OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.

Renal action / finding
eGFR >=30 mL/min/1.73 m2: no renal adjustment.
Evidence or dialysis limit
eGFR <30 not studied; no dialysis regimen established.
Monitoring / application
Use age-appropriate Schwartz/MDRD interpretation and the labeled oncology regimen.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population
OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.
Renal measure
Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

eGFR <30 not studied; no dialysis regimen established.

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Section 8.7

No dose adjustment is recommended for mild-to-moderate impairment with eGFR >=30 mL/min/1.73 m2 using Schwartz or MDRD. Severe impairment below 30 has not been studied. No dialysis regimen is supplied. Use the labeled pediatric oncology indication, BSA-based regimen and appropriate oral presentation; the renal statement does not provide a complete treatment protocol.

Source revision: Revision date not captured in selected review; retrieval date is not revision date. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad

Scope: Selected sections checked against the identified source; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

OJEMDA: selected primary-label renal guidance and limits

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

OJEMDA: selected RX renal passage

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

OJEMDA: selected primary-label renal guidance and limits

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

eGFR <30 not studied; no dialysis regimen established.

Dialysis evidence: No dialysis regimen established in selected content

OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.

Renal method: Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

OJEMDA: selected RX renal passage

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding

eGFR <30 not studied; no dialysis regimen established.

Dialysis evidence: No dialysis regimen established in selected content

OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.

Renal method: Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

OJEMDA: source applicability and renal evidence limits

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

OJEMDA: source applicability and renal evidence limits

The primary label has an explicit renal-use recommendation; the retrieved mirror passage is PK-only. Absence of that section in the returned mirror text is not proof of disagreement.

How to use this: Use age-appropriate Schwartz/MDRD interpretation and the labeled oncology regimen.

OJEMDA: selected primary-label renal guidance and limitsOJEMDA: selected RX renal passage

Selected-source comparison; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

OJEMDA: selected primary-label renal guidance and limits

OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.

Method: Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label

Read this complete source summary
Rxlist source

OJEMDA: selected RX renal passage

OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.

Method: Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label

Specific Populations / renal PKRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeOJEMDA: selected primary-label renal guidance and limitsOJEMDA: selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

An RX mirror and its underlying label are not independent clinical confirmations.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad

Product identity and scope

OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.

RDM72-tovorafenib-ojemda-scope · Source section: Product identity and scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

OJEMDA: selected primary-label renal guidance and limits

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.

Renal method: Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Source date: Revision date not captured in selected review; retrieval date is not revision date.
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

eGFR <30 not studied; no dialysis regimen established.

Dialysis evidence: No dialysis regimen established in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 8.7

No dose adjustment is recommended for mild-to-moderate impairment with eGFR >=30 mL/min/1.73 m2 using Schwartz or MDRD. Severe impairment below 30 has not been studied. No dialysis regimen is supplied. Use the labeled pediatric oncology indication, BSA-based regimen and appropriate oral presentation; the renal statement does not provide a complete treatment protocol.

RDM72-tovorafenib-ojemda-label-1 · Source locator: Section 8.7

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad
Retrieved
2026-11-07
Renal-function method
Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Source date/version
Revision date not captured in selected review; retrieval date is not revision date.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
270feb55937caedcc7fe7438db1961e7431a1f63240c15dcde9d3521ce36467b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

OJEMDA: selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.

Renal method: Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding

eGFR <30 not studied; no dialysis regimen established.

Dialysis evidence: No dialysis regimen established in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Specific Populations / renal PK

The retrieved mirror offers a PK observation for mild/moderate impairment, not the fuller renal-use wording of the primary label. It is retained as PK-only and not substituted for the label renal instruction.

RDM72-tovorafenib-ojemda-rx-1 · Source locator: Specific Populations / renal PK

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/ojemda-drug/
Retrieved
2026-11-07
Renal-function method
Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
4df6f351615877655e5f5b5382fb3cf1251429e7fe0f1048e817f61d201f9c97

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad
Source retrieval
2026-11-07. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
47c728aeeb028a96b549494bd4d5b340a4c449d6cfa77b3c97eec32bb69c84b4
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top